VCAM1 and metabolic dysfunction-associated steatohepatitis: The increase of miR-let-7c-5p is predicted to target the VCAM1 gene, and pharmacological inhibition or genetic deletion of VCAM1 in liver endothelial cells reduced liver inflammation, injury, and fibrosis in mice with NASH [133].